CLRO is trading at $13.02 (5.9% down) in pre-market following a series of sharp moves linked to its planned reverse merger with Cortigent.
- The stock has experienced heavy trading and event-driven volatility as investors engage in profit-taking after the initial deal-related price spike.
- Traders are reassessing post-merger ownership and risk profiles amid ongoing legal scrutiny regarding the merger terms.